April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Effectiveness of Topical AICA-Ribonucleotide in a Mouse Model of Experimental Dry Eye
Author Affiliations & Notes
  • Mi Sun Sung
    Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
  • Zhengri Li
    Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
  • Jee Myung Yang
    Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
  • Ji Suk Choi
    Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
  • In-Cheon You
    Ophthalmology, Chonbuk National University Medical School and Hospital, Jeonju, Republic of Korea
  • Kyung Chul Yoon
    Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea
  • Footnotes
    Commercial Relationships Mi Sun Sung, None; Zhengri Li, None; Jee Myung Yang, None; Ji Suk Choi, None; In-Cheon You, None; Kyung Chul Yoon, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3652. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mi Sun Sung, Zhengri Li, Jee Myung Yang, Ji Suk Choi, In-Cheon You, Kyung Chul Yoon; Effectiveness of Topical AICA-Ribonucleotide in a Mouse Model of Experimental Dry Eye. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3652.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the efficacy of a topical AICA-Ribonucleotide (AICAR) in a mouse model of experimental dry eye (EDE)

Methods: Eye drops consisting of 0.001% and 0.01% AICAR, or 0.05% cyclosporin (CsA) were applied in EDE. Tear volume, tear film break-up time (TBUT) and corneal fluorescein staining scores were measured at 10 days after treatment. Levels of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, monokine induced by interferon-γ (MIG) and Interferon gamma-induced protein 10 (IP-10) were measured in the conjunctiva using a multiplex immunobead assay. Periodic acid-Schiff staining, immunofluorescence staining and flow cytometry were also performed.

Results: Mice treated with 0.01% AICAR showed a significant improvement in tear volume, TBUT and corneal fluorescein staining scores compared with the EDE control and other treatment groups. A significant decrease in the levels of IL-1β, IL-6, TNF-α, IFN-γ, MIG and IP-10 and the number of CD11b+ and CD4+CXCR3+ cells and an increase in goblet cell density was observed in the 0.01% AICAR-treated group, compared with the control and other treatment groups. 0.05% CsA also led to an improvement in the tear and corneal signs and inflammatory molecules compared with the control. However, there were no significant differences in all parameters between the 0.001% AICAR and EDE control groups.

Conclusions: Topical application of 0.01% AICAR could markedly improve clinical signs and decrease inflammation in the ocular surface of EDE, suggesting that AICAR eye drops may be used as a therapeutic agent for dry eye disease.

Keywords: 486 cornea: tears/tear film/dry eye • 490 cytokines/chemokines • 557 inflammation  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×